Epigenetic modulation of immunotherapy and implications in head and neck cancer

B cells are associated with survival and immunotherapy response in sarcoma

(2020) Florent Petitprez et al.   NATURE

Tertiary lymphoid structures improve immunotherapy and survival in melanoma

(2020) Rita Cabrita et al.   NATURE

B cells and tertiary lymphoid structures promote immunotherapy response

(2020) Beth A. Helmink et al.   NATURE

Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice

(2020) Sharmilla Devi Jayasingam et al.   Frontiers in Oncology

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

(2020) R.L. Ferris et al.   ANNALS OF ONCOLOGY

Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition

(2019) Daisuke Ennishi et al.   Cancer Discovery

Landscape of B cell immunity and related immune evasion in human cancers

(2019) Xihao Hu et al.   NATURE GENETICS

Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer

(2019) Swathi Ramakrishnan et al.   CELL DEATH AND DIFFERENTIATION

Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040)

(2019) Sara I. Pai et al.   Journal for ImmunoTherapy of Cancer

Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials

(2019) Jia-Wei Lv et al.   Journal for ImmunoTherapy of Cancer

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)

(2019) Ezra E. W. Cohen et al.   Journal for ImmunoTherapy of Cancer

Prognostic Significance of Tumor-Associated Macrophage Content in Head and Neck Squamous Cell Carcinoma: A Meta-Analysis

(2019) Ayan Tyagi Kumar et al.   Frontiers in Oncology

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

(2019) Marian L. Burr et al.   CANCER CELL

Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer

(2019) Danyang Sun et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells

(2019) Matthew B. Dong et al.   CELL

Targeting EZH2 enhances antigen presentation, antitumor immunity and circumvents anti-PD-1 resistance in head and neck cancers

(2019) Liye Zhou et al.   CLINICAL CANCER RESEARCH

Neoantigen vaccine: an emerging tumor immunotherapy

(2019) Miao Peng et al.   Molecular Cancer

Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

(2019) Spencer C. Wei et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

In vivo epigenetic CRISPR screen identifies Asf1a as an immunotherapeutic target in Kras-mutant lung adenocarcinoma

(2019) Fei Li et al.   Cancer Discovery

A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer

(2019) Cristina P. Rodriguez et al.   CLINICAL CANCER RESEARCH

Mechanisms of resistance to immune checkpoint inhibitors

(2018) Russell W Jenkins et al.   BRITISH JOURNAL OF CANCER

LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade

(2018) Wanqiang Sheng et al.   CELL

Epigenetic regulation in B-cell maturation and its dysregulation in autoimmunity

(2018) Haijing Wu et al.   Cellular & Molecular Immunology

Inhibition of histone H3K27 demethylases selectively modulates inflammatory phenotypes of natural killer cells

(2018) Adam Cribbs et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Inhibition of Enhancer of zeste homolog 2 (EZH2) induces natural killer cell-mediated eradication of hepatocellular carcinoma cells

(2018) Suresh Bugide et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

A major chromatin regulator determines resistance of tumor cells to T cell–mediated killing

(2018) Deng Pan et al.   SCIENCE

The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients

(2018) Vyara Matson et al.   SCIENCE

DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer

(2018) Na Luo et al.   Nature Communications

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer Immunity

(2018) David Wang et al.   Cell Reports

Combination Immunotherapy: Taking Cancer Vaccines to the Next Level

(2018) Jeremy M. Grenier et al.   Frontiers in Immunology

Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination

(2018) Jun Gong et al.   Journal for ImmunoTherapy of Cancer

Metastatic uveal melanoma showing durable response to anti-CTLA-4 and anti-PD-1 combination therapy after experiencing progression on anti-PD-1 therapy alone

(2018) Muhammad Zubair Afzal et al.   Journal for ImmunoTherapy of Cancer

Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy

(2018) Sangeeta Goswami et al.   JOURNAL OF CLINICAL INVESTIGATION

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

JAVELIN Head and Neck 100: a Phase III trial of avelumab and chemoradiation for locally advanced head and neck cancer

(2018) Yao Yu et al.   Future Oncology

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy

(2018) Diane Evrard et al.   ORAL ONCOLOGY

Polycomb Repressive Complex 2-Mediated Chromatin Repression Guides Effector CD8 + T Cell Terminal Differentiation and Loss of Multipotency

(2017) Simon M. Gray et al.   IMMUNITY

Myeloid-derived suppressor cells—a new therapeutic target to overcome resistance to cancer immunotherapy

(2017) Jason A. Chesney et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Identification of essential genes for cancer immunotherapy

(2017) Shashank J. Patel et al.   NATURE

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

(2017) Robert T. Manguso et al.   NATURE

Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck

(2017) Glenn J. Hanna et al.   ORAL ONCOLOGY

Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells

(2017) Cornelia Siebenkäs et al.   PLoS One

Epigenetic therapy activates type I interferon signaling in murine ovarian cancer to reduce immunosuppression and tumor burden

(2017) Meredith L. Stone et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy

(2017) Diego Chowell et al.   SCIENCE

Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients

(2017) V. Gopalakrishnan et al.   SCIENCE

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

(2017) Bertrand Routy et al.   SCIENCE

Epigenetic Remodeling in Exhausted T Cells

(2017) Sonia J. Laurie et al.   TRANSPLANTATION

Ezh2 phosphorylation state determines its capacity to maintain CD8+ T memory precursors for antitumor immunity

(2017) Shan He et al.   Nature Communications

The Histone Methyltransferase Ezh2 Controls Mechanisms of Adaptive Resistance to Tumor Immunotherapy

(2017) Daniel Zingg et al.   Cell Reports

The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis

(2017) Emma J. de Ruiter et al.   OncoImmunology

Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade

(2016) Haidong Tang et al.   CANCER CELL

Targeted Therapies Combined With Immune Checkpoint Therapy

(2016) Peter A. Prieto et al.   CANCER JOURNAL

Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy

(2016) Jianjun Gao et al.   CELL

Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors

(2016) Jonathan M. Pitt et al.   IMMUNITY

Roles of regulatory T cells in cancer immunity

(2016) Yoshiko Takeuchi et al.   INTERNATIONAL IMMUNOLOGY

Immunological and clinical significance of HLA class I antigen processing machinery component defects in malignant cells

(2016) Fernando Concha-Benavente et al.   ORAL ONCOLOGY

Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade

(2016) K. E. Pauken et al.   SCIENCE

PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations

(2016) Weiping Zou et al.   Science Translational Medicine

IFN-γ Induces Histone 3 Lysine 27 Trimethylation in a Small Subset of Promoters to Stably Silence Gene Expression in Human Macrophages

(2016) Yu Qiao et al.   Cell Reports

HDACs and HDAC Inhibitors in Cancer Development and Therapy

(2016) Yixuan Li et al.   Cold Spring Harbor Perspectives in Medicine

International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

(2015) H. Dombret et al.   BLOOD

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

(2015) Suzanne L. Topalian et al.   CANCER CELL

Classifying Cancers Based on T-cell Infiltration and PD-L1

(2015) Michele W.L. Teng et al.   CANCER RESEARCH

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts

(2015) David Roulois et al.   CELL

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

(2015) Katherine B. Chiappinelli et al.   CELL

The Chromatin-Modifying Enzyme Ezh2 Is Critical for the Maintenance of Regulatory T Cell Identity after Activation

(2015) Michel DuPage et al.   IMMUNITY

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy

(2015) Shabnam Shalapour et al.   NATURE

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Cancer mediates effector T cell dysfunction by targeting microRNAs and EZH2 via glycolysis restriction

(2015) Ende Zhao et al.   NATURE IMMUNOLOGY

Ezh2 regulates differentiation and function of natural killer cells through histone methyltransferase activity

(2015) Jie Yin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy

(2015) A. Sivan et al.   SCIENCE

Neoantigens in cancer immunotherapy

(2015) T. N. Schumacher et al.   SCIENCE

EZH2 is crucial for both differentiation of regulatory T cells and T effector cell expansion

(2015) Xiang-Ping Yang et al.   Scientific Reports

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers

(2015) Huili Li et al.   Oncotarget

Presence of B Cells in Tertiary Lymphoid Structures Is Associated with a Protective Immunity in Patients with Lung Cancer

(2014) Claire Germain et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

SOCS1 hypermethylation mediated by DNMT1 is associated with lipopolysaccharide-induced inflammatory cytokines in macrophages

(2014) Chang Cheng et al.   TOXICOLOGY LETTERS

Anti-CD20 Antibody Promotes Cancer Escape via Enrichment of Tumor-Evoked Regulatory B Cells Expressing Low Levels of CD20 and CD137L

(2013) M. Bodogai et al.   CANCER RESEARCH

B cell regulation of anti-tumor immune response

(2013) Yu Zhang et al.   IMMUNOLOGIC RESEARCH

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

(2013) Omid Hamid et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting DNA Methylation

(2009) J.-P. J. Issa et al.   CLINICAL CANCER RESEARCH